Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Btk inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
Blinded Sample Size Re-estimation in a Phase III Study Inve
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
by maniakti
Richard S. Finn, MD. Professor of Clinical Medicin...
Treatment of
Treatment of
by natalia-silvester
Biliary. Cancers. Abby B. Siegel, MD, MS . Colum...
Department of GI Medical Oncology
Department of GI Medical Oncology
by danika-pritchard
Does . the New EPOC trial . eliminate. . Anti. -...
MEK Inhibitors and their potential role in relapsed NSCLC
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
17th Annual International Congress
17th Annual International Congress
by conchita-marotz
on . Hematologic Malignancies. ®. : . Focus . on...
ASCO 2010:
ASCO 2010:
by phoebe-click
. Highlights from the Annual Clinical Meeting. G...
William J.
William J.
by tawny-fly
Gradishar. . MD, FACP. Betsy . Bramsen. Profess...
Please note, these are the actual video-recorded proceeding
Please note, these are the actual video-recorded proceeding
by luanne-stotts
Moderator. Neil Love, MD. Mollie Moran, MSN, CNP,...
State of the Art in BRCA
State of the Art in BRCA
by ellena-manuel
-Mutated Ovarian Cancer. This program will includ...
Case Discussion: Second
Case Discussion: Second
by celsa-spraggs
Opinion. 55 year-old woman with . recurrent . ova...
Overall Survival Benefit of
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
NEw developments IN gynecological Oncology
NEw developments IN gynecological Oncology
by cheryl-pisano
highlights from the. EUROPEAN . society . of med...
Romidepsin in Association with CHOP in Patients with Peripheral T
Romidepsin in Association with CHOP in Patients with Peripheral T
by accompanypepsi
-Cell . Lymphoma: Final Results of the Phase . Ib....
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
Ovarian Cancer: Standards of Care and New Opportunities
Ovarian Cancer: Standards of Care and New Opportunities
by majerepr
Robert L. Coleman, M.D.. Professor & . Vice Ch...
GIULIANA D’AURIA UOC Oncologia ASL Roma 2
GIULIANA D’AURIA UOC Oncologia ASL Roma 2
by hadley
Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . app...
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
by zen
knowledge. ). Incorporate evidence-based research ...